MedPath

Comparison of drug Dexmedetomidine and Fentanyl as an adjuvant to Ropivacaine in epidural space for post operative pain relief in abdominal hysterectomy patients.

Phase 2
Not yet recruiting
Conditions
Medical and Surgical,
Registration Number
CTRI/2022/01/039726
Lead Sponsor
Rajendra Institute of medical sciences
Brief Summary

This prospective, randomised controlled, double blind study will be conducted on 60 patients belonging to the ASA physical status 1 or 2, aged 30 - 60 years posted for elective abdominal hysterectomy.

Pre-anaesthetic check up will be done a day before surgery including a detailed history,a thorough physical and systemic examination. Routine investigations will include CBC, routine urine test, ECG, serum urea, serum creatinine, blood sugar and chest radiograph. In the operating room standard monitoring will be established (ECG, Non-invasive Blood pressure, pulse oximetry) and baseline measurements will be recorded. Under aseptic precautions, epidural catheter will be placed using 18 G Touhy needle with patients in the sitting position in L3-L4 interspace and location of epidural space will be confirmed using loss of resistance technique. A test dose of 3 ml of 2% Lignocaine with adrenaline will be administered into epidural space and thereafter epidural catheter will be secured 3 to 5 cm into epidural space and patient will be placed in the supine position. Heart rate, mean arterial pressure, SPO2 will be recorded using standard monitors before and after epidural test dose. General anaesthesia will be induced with Propofol (1.5-2mg/kg) + Succinyl choline(1.5mg/kg) + Fentanyl (2 µg/kg) and maintained with O₂, N₂O and Isoflurane. Muscle relaxation will be done with vecuronium 4mg and then 1mg intermittently. The respective drugs depending on the group allocated will be given by epidural infusion at the rate of 7ml/hr (Ropivacaine (0.125 %) +1µg/ml Dexmedetomidine or Ropivacaine (0.125%) +2µg /ml Fentanyl) into the epidural space 1hr after the skin incision using syringe pump. After extubation, the patient will be put on PCEA pump with study drug with background infusion

of 5ml/hr(Ropivacaine (0.125 %) +1µg/ml Dexmedetomidine or Ropivacaine (0.125%) +2µg /ml Fentanyl), demand bolus dose of 2ml, lock-out interval of 10 min (Maximum dose=10ml/hr). The degree of motor block will be assessed by the Modified Bromage scale:

Bromage 0 – able to perform a full straight leg raise over the bed for 5 sec

Bromage 1 – unable to perform the leg raise but can flex the leg on the knee articulation.

Bromage 2 – unable to flex the knee but can flex the ankle.

Bromage 3 – unable to flex ankle but can move the toes.

Bromage 4 – unable to move toes (total paralysis).

Post-operative pain scores will be recorded using visual analogue scale (VAS) ranging from 0 to 10 (0 – no pain ,10- worst pain ever) at 0,1,2,4,8,12,16,20,24 hours.

Patients with breakthrough pain will be given 25µg Fentanyl IV bolus. Rescue analgesia requirement will be noted and side effects if any will be addressed accordingly.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
60
Inclusion Criteria

All patients with ASA status type I, II aged between 30-60 who will be undergoing abdominal hysterectomy surgeries.

Exclusion Criteria

a) All patients who are not willing to consent, b) All patients who have a history of allergies to any of the drugs used in the study, c) Bleeding diathesis, uncontrolled hypertension and heart rate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The degree of motor block will be assessed by the Modified Bromage scale1 hr-24hrs
Secondary Outcome Measures
NameTimeMethod
Post-operative pain scores will be recorded using visual analogue scale (VAS) ranging from 0 to 101 hr -24hrs

Trial Locations

Locations (1)

Rajendra institute of medical sciences

🇮🇳

Ranchi, JHARKHAND, India

Rajendra institute of medical sciences
🇮🇳Ranchi, JHARKHAND, India
Dr Shio Priye
Principal investigator
9986743162
shiopriye@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.